Tanaka Akiko, Onsager David, Song Tae, Cozadd Daniel, Kim Gene, Sarswat Nitasha, Adatya Sirtaz, Sayer Gabriel, Uriel Nir, Jeevanandam Valluvan, Ota Takeyoshi
Department of Surgery, University of Chicago Medicine, Chicago, Illinois.
Department of Medicine, University of Chicago Medicine, Chicago, Illinois.
Ann Thorac Surg. 2017 Mar;103(3):725-733. doi: 10.1016/j.athoracsur.2016.06.078. Epub 2016 Sep 19.
Indications for concomitant intervention for mitral regurgitation (MR) during left ventricular assist device (LVAD) implantation remain controversial. The objective of this study was to determine the impact of the surgical correction of MR during LVAD implantation.
From July 2008 to December 2014, 164 patients with significant preoperative MR underwent LVAD (HeartMate II; Thoratec, Pleasanton, CA) implantation. The MR resolved after LVAD implantation in 110 of 164 patients (67.1%) with either surgical or spontaneous correction. The cohort (n = 110) without significant postoperative MR was divided into two groups: a spontaneous correction group (n = 54, MR spontaneously resolved after LVAD implantation); and a surgical correction group (n = 56, MR surgically corrected). Patients who received aortic valve procedures (n = 17) were excluded from this study.
Patient demographics, perioperative outcomes including bleeding, prolonged intubation, and stroke, and inhospital mortality did not differ in the two groups except for significantly longer cardiopulmonary bypass time in the surgical correction group (spontaneous correction 123 minutes [interquartile range (IQR): 107 to 150] versus surgical correction 177 minutes [IQR: 132 to 198], p < 0.001). During follow-up, pulmonary wedge pressure (spontaneous correction 17 mm Hg [IQR: 12 to 23 mm Hg] versus surgical correction 12 mm Hg [IQR: 4 to 17 mm Hg], p = 0.015) and pulmonary vascular resistance (spontaneous correction 2.0 Wood units [IQR: 1.5 to 2.4] versus surgical correction 1.7 Wood units [IQR: 0.8 to 2.1], p = 0.047) were significantly improved in the surgical correction group compared with the spontaneous correction group. Overall survival rate and freedom from recurrent MR were significantly better in the surgical correction group compared with the spontaneous correction group (1-year survival, spontaneous correction 59.4% ± 6.9% versus surgical correction 69.6% ± 6.4%, log rank p = 0.030; 1-year freedom from recurrent MR, spontaneous correction 76.2% ± 7.5% versus surgical correction 95.0% ± 3.5%, log rank p = 0.028).
The LVAD patients with surgically corrected MR had improved midterm hemodynamics and survival compared with spontaneously resolved MR, along with low recurrence of MR. Aggressive surgical mitral valve intervention during LVAD implantation may be recommended.
在左心室辅助装置(LVAD)植入期间,二尖瓣反流(MR)同期干预的指征仍存在争议。本研究的目的是确定LVAD植入期间手术矫正MR的影响。
2008年7月至2014年12月,164例术前有严重MR的患者接受了LVAD(HeartMate II;Thoratec,普莱森顿,加利福尼亚州)植入。164例患者中有110例(67.1%)在LVAD植入后通过手术或自发矫正使MR消失。无明显术后MR的队列(n = 110)分为两组:自发矫正组(n = 54,LVAD植入后MR自发消失);手术矫正组(n = 56,MR通过手术矫正)。接受主动脉瓣手术的患者(n = 17)被排除在本研究之外。
两组患者的人口统计学特征、围手术期结局(包括出血、长时间插管和中风)以及住院死亡率无差异,但手术矫正组的体外循环时间明显更长(自发矫正组123分钟[四分位间距(IQR):107至150],手术矫正组177分钟[IQR:132至198],p < 0.001)。随访期间,手术矫正组的肺楔压(自发矫正组17 mmHg[IQR:12至23 mmHg],手术矫正组12 mmHg[IQR:4至17 mmHg],p = 0.015)和肺血管阻力(自发矫正组2.0伍德单位[IQR:1.5至2.4],手术矫正组1.7伍德单位[IQR:0.8至2.1],p = 0.047)与自发矫正组相比有显著改善。手术矫正组的总体生存率和无复发性MR的自由度明显优于自发矫正组(1年生存率,自发矫正组59.4%±6.9%,手术矫正组69.6%±6.4%,对数秩检验p = 0.030;1年无复发性MR,自发矫正组76.2%±7.5%,手术矫正组95.0%±3.5%,对数秩检验p = 0.028)。
与自发消失的MR相比,手术矫正MR的LVAD患者中期血流动力学和生存率得到改善,且MR复发率较低。建议在LVAD植入期间积极进行二尖瓣手术干预。